← All Repligen CORP filings

Repligen CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RGEN
Repligen CORP
10-K: Repligen Reports Strong 2025 Revenue Growth, Addresses Internal Control Weaknesses
Repligen Corporation announced a 16.4% increase in product revenue for 2025, reaching $737.96 million, alongside the remediation of a material weakness in revenue recognition but ongoing challenges with IT general controls and inventory valuation.
NASDAQ
RGEN
Repligen CORP
10-K: Repligen Reports Mixed Results in 2024 10-K Filing: Revenue Stagnant, Internal Control Weaknesses Identified
Repligen's 2024 10-K filing reveals stagnant revenue growth, offset by increased filtration product revenue, and identifies material weaknesses in internal control over financial reporting.
NASDAQ
RGEN
Repligen CORP
10-K/A: Repligen Restates 2023 Financials, Cites Revenue Recognition and Internal Control Weaknesses
Repligen Corporation files an amended 10-K report restating its 2023 financials due to a misapplication of accounting principles related to revenue recognition and identifies material weaknesses in internal controls.
NASDAQ
RGEN
Repligen CORP
10-K: Repligen Corp. Files 10-K, Details Business Strategy and Financial Health
Repligen Corporation's 10-K filing outlines its business strategy, product portfolio, financial performance, and risk factors for the fiscal year ended December 31, 2023.